Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Lexon Pharmaceuticals (Ireland) Limited, Block 3, Harcourt Centre, Harcourt Road, Dublin 2, Ireland
Lamzarin 30 mg prolonged-release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release Tablet. Lamzarin 30 mg Prolonged-release Tablets are white biconvex capsule shaped tablet with ‘GLI 30’ on one side and plain on other side having dimensions Length 10.00 mm ± 0.15 mm, Breadth 4.50 mm ± 0.15 mm and Thickness: 3.55 mm ± 0.15 mm. |
Lamzarin 30 mg Prolonged-release Tablets.
Each Prolonged-release Tablet contains 30 mg gliclazide.
Excipient with known effect: Each Prolonged-release Tablet contains 81.90 mg lactose (as the monohydrate) (see section 4.4).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Gliclazide |
Gliclazide is a hypoglycaemic sulfonylurea antidiabetic active substance. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans. |
| List of Excipients |
|---|
|
Lactose monohydrate |
PVC/PVDC/Alu blisters.
PVC/Alu blister.
Pack sizes:
Blisters: 14, 28, 56 Prolonged-release Tablets.
Not all pack sizes may be marketed.
Lexon Pharmaceuticals (Ireland) Limited, Block 3, Harcourt Centre, Harcourt Road, Dublin 2, Ireland
PA23176/004/001
Date of first authorisation: 5th April 2019
| Drug | Countries | |
|---|---|---|
| LAMZARIN | Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
